Cumberland logo
Contact
Contact

Guiding Strategy,

Overseeing Operations,

Ensuring Good Governance

Board of Directors

A.J. Kazimi, Chairman of the company, standing confidently with arms crossed and smiling.

A.J. Kazimi

Chairman

A.J. Kazimi is the Chairman of the Board of Directors and Chief Executive Officer of Cumberland Pharmaceuticals Inc., which he founded in 1999. His career includes over 30 years in the biopharmaceutical industry. At Cumberland, he has overseen the development and FDA approval of key Company brands, while also leading the acquisition of the Company’s other commercial products. He was responsible for Cumberland’s initial public offering and listing on the Nasdaq stock exchange.
Kazimi also serves as Chairman and Chief Executive Officer of Cumberland Emerging Technologies – a joint initiative with Vanderbilt University and the state of Tennessee – designed to support the development of early-stage life sciences programs and companies.
Prior to joining Cumberland, he spent 11 years helping to build Therapeutic Antibodies Inc., an international biopharmaceutical company. As President and Chief Operating Officer, he made key contributions to that company’s growth from its startup phase through its initial public offering and listing on the London stock exchange. Kazimi started his career at Brown-Forman Corporation, rising through a series of management positions.
He is Chairman of the Board for the Gettysburg Foundation, which partners with the National Park Service to preserve their historic military park. He is also a member of the Board of the Tennessee Historical Society and the Owen Advisory Council at the Vanderbilt University Business School.
He previously served on the Board of Directors for the Nashville Health Care Council, an association of the largest concentration of health care companies in the U.S., and the Board of Aegis Sciences Corporation, a federally certified forensic toxicology laboratory, which has twice been sold to private equity investors. Kazimi holds an MBA from the Vanderbilt University Owen Graduate School of Management and a B.S. from the University of Notre Dame.
Kazimi brings strategic insight, leadership, and a history of successful execution to the Company along with a wealth of experience in both the biopharmaceutical industry and the development of emerging companies.
Kenneth J. Krogulski, Director, wearing a suit and tie, looking confidently into the camera in a professional office environment.

Kenneth J. Krogulski

Director

Kenneth Krogulski joined Cumberland’s Board of Directors in 2017. He has over 40 years of experience in security analysis and portfolio management and is currently the Managing Partner and Chief Investment Officer of Berkshire Asset Management, LLC. Berkshire is an independent SEC-registered, Pennsylvania-based investment advisory firm.

Prior to Berkshire, Krogulski began his career in financial services in 1979 at First Eastern Bank, N.A., now PNC Financial, as an investment analyst and portfolio manager, where he advanced to Chief Investment Officer of the Trust Department.

In addition, Krogulski is currently on the Board of Allied Services Integrated Health System. He previously served as a director of Landmark Community Bank (Nasdaq: LDKB) and numerous nonprofit organizations. He holds an MBA from Wilkes University and earned a B.S. in finance from Indiana University of Pennsylvania. In addition, he holds the Chartered Financial Analyst designation.

Krogulski’s extensive financial experience plays a significant role in guiding Cumberland’s strategy and offers valuable services in directing the Company’s growth.

Gordon R. Bernard, M.D., Director, sitting at a table and smiling in a professional office environment.

Gordon R. Bernard, M.D.

Director

Dr. Gordon Bernard served as Cumberland’s Medical Director from 1999 until 2010 and currently serves as Chair of our Medical Advisory Board. He has served on our Board of Directors since 2010. Bernard is currently the Melinda Owen Bass Professor of Medicine for the Division of Pulmonary & Critical Care Medicine for Vanderbilt University Medical Center and former Chief of the Division.

In addition, he was formerly the Executive Vice President for Research, Chief Research Officer, Senior Associate Dean for Clinical Sciences, and Chairman of Vanderbilt’s Pharmacy and Therapeutics Committee, which is responsible for approving the Vanderbilt Medical Center formulary of approved drugs and therapeutics.

Bernard has been conducting national and international trials of pharmaceuticals since 1980 and he was the Steering Committee Chair of the National Institutes of Health, Acute Respiratory Distress Syndrome Clinical Trials Network since its inception in 1994 through its conclusion in 2014. This network was the only federally supported ongoing system for the conduct of research in the hospital intensive care unit. As an intensivist and former Medical Director for the medical intensive care unit, Bernard is therefore in a strategic position to observe, firsthand, the pharmaceutical management issues surrounding the care of a wide variety of the most severely ill patients and identify their unmet medical needs. He holds an M.D. from Louisiana State University and a B.S. from the University of Southwestern Louisiana.

Bernard’s medical background is extremely valuable as Cumberland seeks to continue expanding its pipeline with promising products that offer advancement in patient care and are well-positioned competitively.

James R. Jones, Director, wearing a suit and patterned tie, smiling in a professional office setting.

James R. Jones

Director

James Jones has served as a member of Cumberland’s Board of Directors since 2010. Jones’ 36-year career in professional accounting at KPMG LLP included the role of Managing Partner at their Nashville, Tennessee office from 1999 to 2006. 

He served in various capacities during his career at KPMG, which also included positions at their offices in Jackson, Mississippi, Washington, D.C., and Greenville, South Carolina. During his tenure with KPMG, Jones led a team of more than 100 individuals providing accounting services for an extensive client base. 

Following retirement in 2006, he has served as an advisor as well as provided various consulting services to several companies, including acting as liaison between management and the Board of Directors of a long-term care facility and serving as interim CEO of a charitable organization. 

He is currently a Board Director and member of the audit committees of Argent Trust Company of Tennessee and Belmont University. Jones also serves as a member of Cumberland’s audit committee and is our audit committee financial expert. He holds an MBA from Mississippi State University and a B.S. from Mississippi College.  

Jones’ significant accounting background strengthens Cumberland’s financial capabilities and plays a key role as the Company is subject to increasingly stringent accounting and auditing regulations as a public entity.

Caroline R. Young, Director, smiling with arms crossed, wearing a professional suit.

Caroline R. Young

Director

Caroline Young joined Cumberland’s Board of Directors in 2016. Young brings two decades of health care and life sciences experience to the role.
Currently, she serves as Vice President of Partnership Development with Frist Cressey Ventures (FCV), where she focuses on accelerating value for FCV’s partnerships and enhancing relationships with health care stakeholders. Before joining FCV, Young partnered with Former U.S. Senate Majority Leader Bill Frist to launch NashvilleHealth, a first-of-a-kind initiative to reduce disparities and drive community-level health improvement.
Prior to that role, Young led one of the nation’s premier health care industry associations as president of the Nashville Health Care Council, where she cultivated a national network of executives in support of leadership and innovation. She has also held prior positions as the founding Executive Director of Life Science Tennessee and director of communications and advertising at the State of Tennessee’s Department of Economic and Community Development.
Young currently serves on the Board of Hint Health, is a member of the advisory boards of Belmont University College of Health Sciences and Washington, DC-based Women Business Leaders of the U.S. Healthcare Industry. She holds an M.S. from the University of Tennessee and a B.A. from the University of Mississippi.
Young’s national health care industry experience and strategic innovation initiatives are valuable as Cumberland continues to build a strong portfolio of products that serve the health care community.
Joseph C. Galante, Director, smiling with arms crossed, wearing a suit and patterned tie in a professional setting.

Joseph C. Galante

Director

Joseph Galante has served as a member of Cumberland’s Board of Directors since 2018. He is a music industry executive with extensive experience that spans a celebrated career. He is accredited with developing the careers of Alabama, Dave Mathews Band, Dolly Parton, Kenny Chesney, Brad Paisley, Martina McBride, Carrie Underwood, Clint Black, Miranda Lambert and The Judds, among others.

Galante began at RCA Records in New York, followed by a transfer to RCA Nashville where he served as a director at the label, followed by the role of Vice President of Promotion and Marketing. At 32 years of age, he became the youngest person ever named to run a major country music record label.

In 1990 RCA Records US appointed Galante President of the New York-based company. He returned to Nashville as Chairman to run the RCA and BNA labels in town. Under his leadership, RCA Records was the number one country label for 11 consecutive years. He then served as Chairman of Sony Music Nashville for six years.

The Opry Trust presented Galante with the Bob Kingsley Living Legend Award to honor his work for country music. Then, in 2022, he was presented with the esteemed honor of being inducted into the Country Music Hall of Fame. He is currently a member of the Board of Directors of Pinnacle Financial Partners, whose shares are listed on the Nasdaq stock exchange, and Fishbowl Spirits. Galante also serves as the Chair of the Country Music Association Foundation. He holds a B.S. in finance and marketing from Fordham University.

Galante’s successful business record, entrepreneurial and public company experience make him a valuable member of Cumberland’s Board.

Martin S. Brown, Director, smiling in a suit and patterned tie.

Martin S. Brown

Director

Martin Brown joined the Cumberland Pharmaceuticals Board of Directors in September of 2022. He joined Adams and Reese law firm in 1994 and
primarily represents privately held businesses and their owners. His experience includes the licensing
of intellectual property, international commerce, mergers and acquisitions and estate planning matters. He also advises on the private placement of securities and the implementation of stock option plans for employees.
Brown is an experienced health care attorney, having represented specialty pharmaceutical companies conducting financings and licensing rights to specialized technology, a biotechnology company in a dispute over intellectual property rights and a foreign medical device manufacturer developing domestic distribution arrangements.
His credits also include service on the Board of Directors of the parent company of Aegis Sciences Corporation since 2018 and of Brown-Forman Corporation, a NYSE-listed company, from 2006 until 2016. He is a former director of Centerstone Mental Health Center, then the tenth largest behavioral health provider in the nation. He served as President of the Yale Club of Middle Tennessee and is a member of the Economic Club of Nashville. Brown holds a J.D. from Vanderbilt University Law School and a B.A. from Yale University. Brown’s significant legal knowledge and experience with a publicly listed company are critical as Cumberland continues to navigate the responsibilities associated with being a public company.

© 2024 Cumberland Pharmaceuticals Inc. All Rights Reserved.